Sionna Therapeutics, Inc./$SION
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sionna Therapeutics, Inc.
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
Ticker
$SION
Sector
Primary listing
Employees
41
Headquarters
Website
SION Metrics
BasicAdvanced
$1B
-
-$3.79
-
-
Price and volume
Market cap
$1B
52-week high
$26.50
52-week low
$7.26
Average daily volume
228K
Financial strength
Current ratio
35.331
Quick ratio
34.778
Long term debt to equity
2.398
Total debt to equity
2.746
Profitability
EBITDA (TTM)
-87.04
Management effectiveness
Valuation
Price to book
2.99
Price to tangible book (TTM)
2.99
Price to free cash flow (TTM)
-7.132
Free cash flow yield (TTM)
-14.02%
Free cash flow per share (TTM)
-3.201
Growth
Bulls say / Bears say
Reported positive Phase 1 results for first-in-class NBD1 stabilizers SION-719 and SION-451, which were generally well tolerated and surpassed pharmacokinetic targets in healthy volunteers (GlobeNewswire)
Maintains a strong balance sheet with $337.3 million in cash and equivalents as of June 30, 2025, which funds operations through 2028 and supports ongoing R&D (GlobeNewswire)
Well-structured near-term catalyst pipeline: Phase 2a proof-of-concept trial for SION-719 and combination MAD trials for SION-451 remain on schedule for the second half of 2025, providing multiple data readouts (GlobeNewswire)
Pipeline remains in Phase 1, with proof-of-concept and combination MAD (multiple ascending dose) results not expected until mid-2026, pushing back key clinical validation and regulatory milestones (GlobeNewswire)
High rate of cash usage; net loss widened to $18.1 million in Q2 2025, compared to $8.6 million in the prior year, reflecting significant R&D spending without any revenue to offset expenses (GlobeNewswire)
Faces strong competition from Vertex’s cystic fibrosis franchise, which is projected to generate $11.75 billion–$12 billion in 2025, making it challenging for a new CFTR modulator to capture market share (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sionna Therapeutics, Inc. stock?
Sionna Therapeutics, Inc. (SION) has a market cap of $1B as of September 15, 2025.
What is the P/E ratio for Sionna Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Sionna Therapeutics, Inc. (SION) stock is 0 as of September 15, 2025.
Does Sionna Therapeutics, Inc. stock pay dividends?
No, Sionna Therapeutics, Inc. (SION) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next Sionna Therapeutics, Inc. dividend payment date?
Sionna Therapeutics, Inc. (SION) stock does not pay dividends to its shareholders.
What is the beta indicator for Sionna Therapeutics, Inc.?
Sionna Therapeutics, Inc. (SION) does not currently have a Beta indicator.